Neurobiologists Evaluate Possible New Treatment for Myasthenia Gravis

Current treatment options include steroids, intravenous immunoglobulins, and surgical removal of the thymus gland. All of these options are accompanied by possibly severe side effects.

In the current study investigators at Saint Louis University (MO; USA) used a rat model of experimentally acquired myasthenia gravis (EAMG) to evaluate the possible benefits of the C5 complement inhibitor rEV576, a protein originally derived from tick saliva. They reported in the February 4, 2009, online edition of the journal Annals of Neurology that administration of rEV576 to rats with a passive form of EAMG reduced disease severity as evinced by 100% survival rate and a low disease severity score. In active EAMG, rats with severe and mild EAMG were protected from worsening of the disease and had limited weight loss. Serum complement activity in severe and mild EAMG was reduced to undetectable levels during treatment, and deposition of complement components at the neuromuscular junction was reduced. Treatment with rEV576 resulted in reduction of toxicity of serum from severe and mild EAMG rats.

"Complement inhibitors are a completely new class of drugs," said senior author Dr. Henry Kaminski, professor of neurology and psychiatry at the University of Saint Louis. "This one will probably prove to be superior to what we have seen. Since complement is activated in many diseases such as Alzheimer's, stroke, and rheumatoid arthritis, our studies may be important for other diseases."

"This disease can leave patients weak and on breathing machines, and conventional treatments can be toxic," said Dr. Kaminski. "There is a real need for better treatments. This study is a step in that direction."

Related Links:
Saint Louis University